Advertisement

Clinical and Experimental Medicine

, Volume 15, Issue 3, pp 255–260 | Cite as

Early and repeated IgG1Fc-pCons chimera vaccinations (GX101) improve the outcome in SLE-prone mice

  • Francesca Ferrera
  • Daniela Fenoglio
  • Maurizio Cutolo
  • Giuseppe Balbi
  • Alessia Parodi
  • Florinda Battaglia
  • Francesca Kalli
  • Domenico Barone
  • Francesco Indiveri
  • Domenico Criscuolo
  • Gilberto FilaciEmail author
Original Article

Abstract

A previous study showed that a tolerogenic gene vaccine based on a IgG1Fc-pCons chimera (here named GX101) protects NZB/NZW mice from SLE development. The present study was aimed at identifying the most effective schedule of immunization and the possible involvement of CD4+ Foxp3+ Treg in the mechanism of action, in view of its eventual translation to the human studies. NZB/NZW mice were vaccinated with B lymphocytes made transgenic by spontaneous transgenesis with a gene coding for a chimeric IgG1Fc-pCons construct. Different schedules of vaccination were set in relation to the timing and number of administrations. Survival, proteinuria levels, and CD4+ Foxp3+ Treg frequency were monitored during the full experiments. GX101-treated mice showed delayed disease onset and delayed mortality than controls. GX101 effects were implemented by early as well as repeated vaccine administrations. GX101 vaccination was associated with increased frequencies of CD4+ CD25+ Foxp3+ Treg with respect to controls. This study demonstrates that early and repeated immunizations with GX101 vaccine provide a better outcome than late or single vaccine administration regarding onset/development in SLE-prone mice, acting as a possible disease-modifying approach. Vaccine effects are likely related to CD4+ Foxp3+ Treg cell expansion.

Keywords

SLE DNA vaccination Immune tolerance Treg DMARD 

Notes

Acknowledgments

This work was supported by a grant from Compagnia di San Paolo, Torino, entitled “Immunoterapia anti-tumorale: analisi d’efficacia dei principali protocolli tradizionali d’immunizzazione e validazione dell’efficacia dell’inibizione dell’interleuchina 10 nel trattamento del melanoma”, and by a grant from Genovax s.r.l. entitled “Analisi fenotipiche e funzionali su linfociti di topi lupus-prone sottoposti a differenti trattamenti vaccinali a scopo tollerogenico”.

Conflict of interest

GX101 has been licensed by the University of Genoa and the University of California, Los Angeles (UCLA), to Genovax s.r.l. Domenico Criscuolo is the President of Genovax; Domenico Barone is the consultant of Genovax for animal studies. Gilberto Filaci, Francesco Indiveri, Daniela Fenoglio, and Giuseppe Balbi are stockholders of Genovax; however, they worked at the project as academics so that they did not receive any payment by Genovax. These authors have no additional financial interests. All the other authors have no conflicting financial interests.

References

  1. 1.
    Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallance DJHB, editor. Dubois’ lupus erithematosus. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 87–96.Google Scholar
  2. 2.
    Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol. 2001;166:6452–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003;21:273–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+ CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scan J Immunol. 2004;59:198–202.CrossRefGoogle Scholar
  5. 5.
    Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2006;27:110–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Monk CR, Spachidou M, Rovis F, Leung E, Botto M, Lechler RI, et al. MRL/Mp CD4+ CD25-T cells show reduced sensitivity to suppression by CD4+ CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthr Rheum. 2005;52:1180–4.CrossRefGoogle Scholar
  7. 7.
    Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthr Rheum. 2001;44:432–41.CrossRefGoogle Scholar
  8. 8.
    Filaci G, Gerloni M, Rizzi M, Castiglioni P, Chang HD, Wheeler MC, et al. Spontaneous transgenesis of human B lymphocytes. Gene Ther. 2004;11:42–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Ferrera F, Hahn BH, Rizzi M, Anderson M, Fitzgerald J, Millo E, et al. Protection against renal disease in (NZB × NZW) F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthr Rheum. 2007;56:1945–53.CrossRefGoogle Scholar
  10. 10.
    Casellas J. Inbred mouse strains and genetic stability: a review. Animal. 2011;5:1–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005;174:3247–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+ CD25+ cells and TGF-beta. Proc Natl Acad Sci USA. 2006;103:8810–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol. 2005;175:7728–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, et al. Modulation of p38 MAP kinase activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB × NZW) F1 lupus mice. J Immunol. 2009;182:7415–21.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • Francesca Ferrera
    • 1
  • Daniela Fenoglio
    • 1
    • 2
  • Maurizio Cutolo
    • 2
  • Giuseppe Balbi
    • 3
  • Alessia Parodi
    • 1
  • Florinda Battaglia
    • 1
  • Francesca Kalli
    • 1
  • Domenico Barone
    • 4
  • Francesco Indiveri
    • 1
    • 2
  • Domenico Criscuolo
    • 3
  • Gilberto Filaci
    • 1
    • 2
    Email author
  1. 1.Centre of Excellence for Biomedical Research (CEBR)University of GenoaGenoaItaly
  2. 2.Department of Internal MedicineUniversity of GenoaGenoaItaly
  3. 3.Genovax s.r.l.Colleretto GiacosaItaly
  4. 4.University of TurinTurinItaly

Personalised recommendations